Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
In one study, 732 patients with primary progressive MS were randomized on a 2:1 ratio to receive either ocrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, or a placebo.
The proportion of patients with 12-week confirmed disability progression was 39.3 per cent with the placebo versus 32.9 per cent with ocrelizumab. After 24 weeks, the proportion with confirmed disability progression was 35.7 per cent with placebo versus 29.6 per cent with ocrelizumab. By week 120, timed 25-foot walk worsened by 55.1 per cent for placebo versus 38.9 per cent for ocrelizumab. Patients given ocrelizumab were also found to have fewer new brain lesions and less brain volume loss than those given the placebo.
Researchers also tested ocrelizumab in two separate studies of patients with relapsing remitting MS, one a group of 821 and the other 835. In both studies, patients were randomized on a 1:1 ratio to receive either ocrelizumab or an already established treatment for relapsing MS: subcutaneous interferon-beta, injected three times weekly. Compared to the placebo, relapse rates in patients given ocrelizumab were 46-per-cent lower in one study and 47-per-cent lower in the other. Ocrelizumab was found to reduce the risk of disability progression after 12 weeks and 24 weeks, and reduced the number of new brain lesions.
The study noted that infusion-related reactions occurred in 34.3 per cent of ocrelizumab-treated patients. Serious infections were not more frequent with ocrelizumab compared to the interferon (1.3 versus 2.9 per cent respectively). Malignancies occurred in four ocrelizumab-treated patients and in two interferon-treated patients. Further observation is required to determine the long-term safety of ocrelizumab.
“The results in patients with relapsing remitting MS not only demonstrate very high efficacy against relapses, but also underscore the important emerging role of B cells of the immune system in the development of relapses,” says Bar-Or. “While the results in patients with primary progressive MS are more modest, they nonetheless represent the very first successful trial in such patients, a breakthrough as primary progressive MS now transitions from a previously untreatable condition to one that can be impacted by therapy. It is an important step forward in the field.”
These studies, funded by Roche, were published in the New England Journal of Medicine on Dec. 21, 2016.
MS in Canada
Canada has one of the world’s highest rates of MS – about 1,100 new cases each year. Some 50,000 Canadians have MS, and more than one-in-five patients are in Quebec. MS is one of the most common neurological diseases among young Canadians. Children as young as two can develop the disease. It typically strikes people in their prime years, between 15 and 40. Women are twice as likely as men to contract MS.
Learn more: Breakthrough in MS treatment
Receive an email update when we add a new MULTIPLE SCLEROSIS article.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprisedon November 20, 2019 at 1:55 am
While new multiple sclerosis drugs from Novartis, Merck KGaA and Biogen have hit the market this year, all bearing blockbuster hopes, one group of doctors wasn't all that interested in them. Instead, ...
- Global Multiple Sclerosis Drugs Market 2019-2023 | Evolving Opportunities with Bayer AG and Biogen | Technavioon November 19, 2019 at 7:48 pm
Technavio has been monitoring the global multiple sclerosis drugs market since 2014 and the market is poised to grow by USD 7.79 billion during 2019-2023 at a CAGR of close to 6% during the forecast ...
- Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pillon November 14, 2019 at 8:00 am
After winning regulatory approval late last month for its new multiple sclerosis drug, Biogen (BIIB) boasted to a patient group that its pill would cost $88,000, which meant it would have the “lowest ...
- BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Societyon November 14, 2019 at 3:00 am
NEW YORK, Nov 14, 2019 (GLOBE NEWSWIRE via COMTEX) -- BrainStorm Cell Therapeutics, Inc. BCLI, +0.00%, a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today ...
- UdeM researchers find molecule to block multiple sclerosis progressionon November 13, 2019 at 5:35 pm
A team of researchers at the Université de Montréal has identified a potential drug target that could safely slow down the progression of multiple sclerosis, a debilitating disease of the central ...
- Slowing the progression of multiple sclerosison November 13, 2019 at 11:03 am
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown. Presently, they have no hope for a cure. In a study published in Science Translational Medicine, ...
- Sports Announcer Dave Johnson Talks About Fighting Multiple Sclerosis, Which His Mother Hadon November 13, 2019 at 7:06 am
Dave Johnson, an unmistakable voice of D.C. sports radio and a beloved member of the News4 family, is battling multiple sclerosis, the same disease his mother struggled with when he was a child. The ...
- High court rules in favor of Singing River patient misdiagnosed with multiple sclerosison November 12, 2019 at 6:12 am
Special Judge James Bell had dismissed a lawsuit attorneys for Debra Green filed in May 2018 against SRHS and Millette over her misdiagnosis of multiple sclerosis. Bell issued the ruling after SRHS ...
- Gundersen Health System hosting free multiple sclerosis programon November 10, 2019 at 7:00 pm
Gundersen Health System is offering a free educational presentation, “A Moment with Mayzent (siponimod),” for people with multiple sclerosis and their friends and family at 6 p.m. Monday, Nov. 25, at ...
via Bing News